Published by Ministry of Health, Labour and Welfare



Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

## Revision of Precautions Duloxetine hydrochloride, Venlafaxine hydrochloride, Milnacipran hydrochloride

November 25, 2016

## Non-proprietary name

- Duloxetine hydrochloride
- Venlafaxine hydrochloride
- Milnacipran hydrochloride

## Safety measure

Precautions should be revised in the package insert.

In the Important Precautions section, the following text should be revised (underlined parts are revised):

As symptoms such as somnolence and dizziness may occur, <u>caution</u> patients <u>about</u> operating hazardous machine such as driving a car. <u>Patients should</u> <u>also be instructed that, if they experience these symptoms, they should not be engaged</u> <u>in hazardous machine operation such as driving a car.</u>

> Pharmaceuticals and Medical Devices Agency Office of Safety I 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>